The European Medicines Agency has recommended approval of NexoBrid (concentrate of proteolytic enzymes enriched in bromelain) from Teva, an orphan-designated...
MediWound announced that it has met its primary and all secondary endpoints in its pivotal U.S. Phase III clinical study...
MediWound Ltd. a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the FDA has approved NexoBrid (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, announced it received a Complete Response Letter (CRL) from the FDA regarding the BLA seeking approval of NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.